ARTICLE | Emerging Company Profile
Laronde: programmable, modular circular RNA therapies
Emerging Company Profile: Flagship launches Laronde with $50M and versatile platform for RNA delivery
May 10, 2021 11:44 PM UTC
While most research on circular RNAs has focused on their use as biomarkers or drug targets, Flagship-backed Laronde debuted Monday to develop circular RNAs as a therapeutic delivery platform that achieves longer-lasting expression than linear mRNA without the immunogenicity of viral vector gene therapies.
Laronde Inc. was founded in 2017 by Flagship Pioneering founder and CEO Noubar Afeyan, the company’s chairman, and Flagship General Partner Avak Kahvejian, its founding CEO. It has since received $50 million from Flagship and is now helmed by Diego Miralles, who joined Flagship as CEO-partner in January...